The Winter 2022 issue of PreferredHealthMagazine featured Dara and her father, Joe’s story of his diagnosis of esophageal cancer and heartbreaking passing. Dara is our Brooklyn, NY Chapter Representative. Dara also included her efforts and work with this mission to raise awareness, encourage early detection and to fund research of esophageal cancer.
Preferred Health Magazine was a presenting sponsor of our 3rd Annual Esophageal Cancer Awareness Run/Walk- NYC in September, 2021.
In addition to sharing Dara’s father’s arduous, valiant and heart wrenching battle with esophageal cancer, it also highlights the importance of awareness of risk factors, symptoms and being your own advocate, especially concerning screening.
‘Tis the season…to have heartburn?! Holiday celebrations often include fun, festivities and food. Sometimes indulging in our favorite foods can mean heartburn. While occasional heartburn may not necessarily be a cause for concern (check with your doctor to make sure), chronic heartburn and other digestive issues may be a symptom of an underlying digestive disorder called Gastroesophageal Reflux Disease or GERD.
GERD can damage the esophagus and increase the risk of more serious digestive diseases, including Barrett’s esophagus and/or esophageal cancer. Many are unaware that chronic heartburn, among other factors, can increase the risk of esophageal cancer.
A lack of awareness of esophageal cancer, paired with the fact that warning symptoms typically appear once the cancer has spread and becomes difficult to treat, makes esophageal cancer one of the fastest growing and deadliest cancers.
While there are currently no routine or standard screenings to detect esophageal cancer, early detection is key. Please speak to your doctor if you have any risk factors or warning signs/symptoms. To learn what tests are used to screen for esophageal cancer, visit: https://salgi.org/screening
For more information on chronic heartburn and the risk of esophageal cancer, visit: SALGI.org/heartburn.
The Salgi Esophageal Cancer Research Foundation: Established in Rhode Island on November 21, 2011, in order to raise awareness, encourage early detection and fund research in hopes of a cure of esophageal cancer; The Salgi Esophageal Cancer Research Foundation is a 501(c)(3) tax exempt nonprofit organization, as recognized by the Internal Revenue Service.
Content found on Salgi.org is for informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Thank you to all who participated in our 3rd Annual Brooklyn, NY Esophageal Cancer Awareness Run/Walk event! Thank you to all who signed up, everyone who created a team, everyone who created a fundraiser, and to everyone who donated.
Special thank you to our Lead Event Coordinator and Brooklyn, NY Chapter Representative Dara for all of her hard work and dedication to this cause! In loving memory of her father, Joe!
Thank you to all who participated in St. Louis, MO’s 5th Annual Billy Bob Trot- Esophageal Cancer Walk/Run!
Thank you to all who signed up, everyone who created a team, everyone who created a fundraiser, and to everyone who donated.
Special thank you to our Lead Event Coordinator Stacey for all of her hard work and dedication to this cause! In loving memory of her father, William!
Thank you, sponsor: duvari group
Thank you, in-kind sponsors:-Susie G’s Specialty Cakes, Hendel’s Market Cafe, The Spotted Pig, Palm Beach Tan, The Yuppy Puppy Pet Spa, O’Fallon Dermatology Specialists, Dynamic Chiropractic & Wellness Center, and Olympia Gymnastic Training Centers.
To all who participated, your efforts are supporting this mission to raise awareness, encourage early detection, and to fund research of esophageal cancer. Stay tuned on our Facebook page for MORE photos from the event! https://www.facebook.com/SalgiFoundation
The 1st Annual Frank Pasquerella Esophageal Cancer Walk/Run took place on Saturday, August 7- Sunday, August 8, 2021.
The event was in honor of Frank Pasquerella—husband, father, son, brother, friend, teacher, and mentor—who passed away from stage IV esophageal cancer. Through this first annual Frank Pasquerella Memorial Walk/Run, the family would like to spread awareness of esophageal cancer, advocate for those families facing this disease, and raise money to help fund research.
Thank you to all who participated in the Virtual 1st Annual Frank Pasquerella Esophageal Cancer Walk/Run! A special thank you to our lead event coordinator, Maria, and her family and friends for putting together a wonderful event! Thank you to all who registered and or donated.
The Salgi Esophageal Cancer Research Foundation has been named a “2021 Top-Rated Nonprofit” by GreatNonprofits, the leading provider of user reviews of charities and nonprofits. The Salgi Esophageal Cancer Research Foundation is a 501(c)(3) nonprofit charity working to raise awareness, encourage early detection and to fund research of esophageal cancer…in hopes of a cure.™
“We are honored to be named a 2021 Top-Rated Nonprofit. We are proud of our accomplishments within the past several years, including awarding esophageal cancer research grants in both 2015 and in 2018; twice in less than seven years since our charity was founded. The research awarded in 2018, a breath test for esophageal cancer, is currently underway.
The Salgi Esophageal Cancer Research Foundation also works to raise awareness, advocates for early detection and has hosted events in Rhode Island, Missouri, Colorado, Ohio, Kentucky, New York City, Massachusetts, Virginia, Maine, New Jersey and Illinois, with additional locations currently in the planning stages. These events gave rise to chapters in St. Louis, Missouri; Arvada, Colorado and Brooklyn, New York.
The Top-Rated Nonprofit Award is the based on the rating and number of reviews The Salgi Esophageal Cancer Research Foundation received from volunteers, donors and supporters. “I appreciate everything that Salgi does to inform the public about the symptoms and screening available so that this disease can be detected earlier rather than later. I appreciate the funding that Salgi provides for research to improve treatments for this disease,” a supporter posted.
“The Salgi Esophageal Cancer Research Foundation is a great example of a nonprofit making a real difference in their community,” said Perla Ni, CEO of GreatNonprofits, “Their award is well-deserved recognition not only of their work, but the tremendous support they receive, as shown by the many outstanding reviews they have received from people who have direct experience working with The Salgi Esophageal Cancer Research Foundation.”
GreatNonprofits is the leading website where people share stories about their personal experiences on more than 1.6 million charities and nonprofits. The GreatNonprofits Top-Rated Awards are the only awards for nonprofits determined by those who have direct experience with the charities – as donors, volunteers and recipients of aid.
The Salgi Esophageal Cancer Research Foundation: Established in Rhode Island on November 21, 2011, in order to raise awareness, encourage early detection and fund research in hopes of a cure of esophageal cancer; The Salgi Esophageal Cancer Research Foundation is a 501(c)(3) tax exempt nonprofit organization, as recognized by the Internal Revenue Service. For more information, please visit: www.salgi.org
About Esophageal Cancer: Acid reflux disease is one of the primary risk factors associated with esophageal cancer. Chronic heartburn, obesity, poor nutrition, tobacco use and excessive alcohol use are all risk factors. Esophageal cancer is among the fastest growing and deadliest cancers in the United States. With over a 733% increase in the past four decades, the overall five-year survival rate is only 19.9%.
There are no standard or routine screenings to detect esophageal cancer in its earlier stages. Symptoms, such as difficulty swallowing, typically appear once the cancer has become advanced. Despite its rapid increase and poor prognosis, esophageal cancer receives very little awareness and research funding.
In 2021, an estimated 19,260 will be diagnosed with esophageal cancer and there will be an estimated 15,530 deaths from esophageal cancer.
The Salgi Esophageal Cancer Research Foundation would like to thank everyone who participated in the Virtual Esophageal Cancer Walk/Run. Thank you to everyone who signed up, everyone who created a team, everyone who created a fundraiser, and to everyone who donated.
Our events are a large part of our fundraising and awareness initiatives and we rely on the generosity of individuals and businesses in our communities to make them a success.
To view guest photos from the event, please visit our Facebook page. Please remember to “like” our Facebook page as well! Click here!
Please join us in thanking our generous sponsor and in-kind sponsors by following the companies below on social media.
The Scott Dye Memorial Topgolf Tournament took place on Saturday, May 8, 2021, at Topgolf in Glendale, Arizona. The event was held to memorialize a great man by raising awareness and research funding for esophageal cancer by supporting The Salgi Esophageal Cancer Research Foundation.
On behalf of The Salgi Esophageal Cancer Research Foundation, we would like to thank everyone who supported The Scott Dye Memorial Top Golf Tournament and give a special thank you to the Dye Family for putting together such a wonderful event.
Thank you in-kind sponsors:
Nothing Bundt Cakes
The Tifin Group
Thank you also to family and friends of the Dye Family for donating gift baskets to the event!
Linda, Michelle, Jennifer and Richard coordinated the event in memory of Scott E. Dye, who passed away from stage IV esophageal cancer on December 13th, 2015. This is their story:
“It seems like just yesterday that we found out our father was diagnosed with esophageal cancer. Our father went to the hospital for chest pain on November 13, 2015 and after the CAT scan was completed, the doctors found a mass on his liver. That is when his primary doctor did more tests (endoscopy) and blood work. The results came back indicating esophageal cancer, Stage IV, on November 30, 2015. Once the cancer was known, there was nothing but vomiting, nausea and dehydration that came from it in the coming days and weeks. We were watching him quickly go downhill just days after he was diagnosed. During this time, a port was put in so that chemotherapy could start and the goal was to FIGHT and beat this nightmare.
By December 9, 2015, he was transported back to the hospital due to a stomach hemorrhage. He was clinging to his life as his kidneys started to fail. Our father was placed in ICU and was too weak to start his chemotherapy. This was all happening too fast and we could not process that he was diagnosed with cancer, let alone that he passed away on December 13, 2015, just a month after symptoms and a diagnosis was given. To see someone you love pass away in front of your eyes is the most unexplainable feeling you can have and you will remember it forever.
We wanted to find a way to help with funding and research. So we have teamed up with The Salgi Esophageal Cancer Research Foundation as a way to raise awareness and remember our father and to help others become aware of symptoms and early detection of cancer.”
Will Lima is the owner of Northeast Barbers in West Warwick, Rhode Island. He and his wife, Karey, are hosting a fundraiser throughout the month of April at the barbershop for The Salgi Esophageal Cancer Research Foundation. Karey’s father, Scott Dutra, passed away from esophageal cancer in 2017. Karey has shared his story below:
Scott (dad) was diagnosed with esophageal cancer on November 23, 2015. As devastating as this diagnosis was, dad was optimistic that he would overcome this disease with the care of his doctor and with the love and support of his children and family. We thought he would have his surgery then go home and have a 2nd chance at life but unfortunately cancer had another plan for him.
Over the next 18 months, Dad would continue to spend most of time in the hospital due to complications. At one point, he was able to spend time with my brother and me at home, eating, laughing, and enjoying his life again. On December 26, 2016 we received the news that the cancer was back, and my dad had up to a year left with us. Dad was able to spend a couple more weeks at home with us but unfortunately, he ended up back in the hospital
My dad passed away on January 24, 2017 and as difficult as it was to lose him; it was equally a blessing because while he fought to the very end he suffered terribly. He is and will be missed every day of our lives. We hope we make you proud, we love you, dad XOXO.
“Today, the U.S. Food and Drug Administration approved Opdivo (nivolumab), in combination with certain types of chemotherapy, for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma. This is the first FDA-approved immunotherapy for the first-line treatment of gastric cancer.
“Today’s approval is the first treatment in more than a decade to show a survival benefit for patients with advanced or metastatic gastric cancer who are being treated for the first time,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Oncologic Diseases in the FDA’s Center for Drug Evaluation and Research. “The FDA is committed to bringing new safe and effective treatment options like Opdivo to patients with advanced cancer.”
In 2021, an estimated 19,260 will be diagnosed with esophageal cancer and there will be an estimated 15,530 deaths from esophageal cancer.¹ The five-year survival rate for all stages of esophageal cancer is 19.9%. Gastric cancer also carries similar, concerning statistics.
“There are approximately 28,000 new diagnoses of gastric cancer each year in the U.S. With currently available therapy, overall survival is generally poor; the rate of cure with resection is very low and the survival rate for all stages is 32%. The 5-year survival rate for advanced or metastatic gastric cancer is 5%.With currently available therapy, overall survival is generally poor; the rate of cure with resection is very low and The 5-year survival rate for advanced or metastatic gastric cancer is 5%.
Opdivo is a monoclonal antibody that inhibits tumor growth by enhancing T-cell function. Its efficacy was evaluated in a randomized, multicenter, open-label trial of 1,581 patients with previously untreated advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma. The 789 patients who received Opdivo in combination with chemotherapy, on average, lived longer than the 792 patients who received chemotherapy alone. Median survival was 13.8 months for patients who received Opdivo plus chemotherapy compared to 11.6 months for patients who received chemotherapy alone.
The most common side effects of Opdivo in combination with chemotherapy include peripheral neuropathy (damage to the nerves outside of the brain and spinal cord), nausea, fatigue, diarrhea, vomiting, decreased appetite, abdominal pain, constipation and musculoskeletal pain. Opdivo can cause serious conditions known as immune-mediated side effects, including inflammation of healthy organs such as the lungs (pneumonitis), colon (colitis), liver (hepatitis), endocrine glands (endocrinopathies) and kidneys (nephritis). Patients should tell their healthcare providers if they have immune system problems, lung or breathing problems, liver problems, have had an organ transplant, or are pregnant or plan to become pregnant before starting treatment.
Opdivo received Priority Review and Orphan Drug designations for this indication. Priority Review designation directs overall attention and resources to the evaluation of applications for drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis or prevention of serious conditions when compared to standard applications. Breakthrough Therapy designation is a process designed to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s).
The FDA granted approval to Bristol-Myers Squibb Company.
This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, the FDA collaborated with the Australian Therapeutic Goods Administration, the Brazilian Health Regulatory Agency, Health Canada and Switzerland’s Swissmedic. The application reviews are ongoing at the other regulatory agencies.
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.”
The Salgi Esophageal Cancer Research Foundation is a 501 (c) (3) non profit organization as recognized by the Internal Revenue Service.
Content found on Salgi.org is for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.